The Patent Finder

Delivery of RNA to Trigger Multiple Immune Pathways

GlaxoSmithKline Biologicals S.A.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 18 of these applications claim priority to application PCT/US2011/043104, filed Jul 6, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,532,067Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · High confidence
UsedRemaining
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,291,682Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,324,770Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,596,645Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 12,186,333Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 9,801,897Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
US 11,690,861Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,690,862Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,690,863Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
US 11,690,864Delivery of RNA to Trigger Multiple Immune Pathways
In force
 · Medium confidence
GlaxoSmithKline Biologicals S.A.In forceMedium confidence
9 more records in this group · Pro
10 of 19 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 19.
Upgrade to Pro
18 of these are in force and held by GlaxoSmithKline Biologicals S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited